Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer

SIMPLE SUMMARY: CDK4/6-inhibitors are an effective first-line treatment for patients with HR+/HER2− metastatic breast cancer (MBC). We aimed to compare overall survival (OS) and progression-free survival (PFS) between three CDK4/6-inhibitors from randomized controlled trials via a graphical reconstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Joseph J., Fong, Khi Yung, Chan, Yiong Huak, Tey, Jeremy, Dawood, Shaheenah, Lee, Soo Chin, Finn, Richard S., Sundar, Raghav, Lim, Joline S. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527344/
https://www.ncbi.nlm.nih.gov/pubmed/37760527
http://dx.doi.org/10.3390/cancers15184558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527344/
https://www.ncbi.nlm.nih.gov/pubmed/37760527
http://dx.doi.org/10.3390/cancers15184558

Ejemplares similares